Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 22:39:65.
doi: 10.1186/1824-7288-39-65.

Is there a role for high dose chemotherapy and blood stem cell rescue in childhood hepatoblastoma presenting with lung metastases? A case report and literature review

Massimo Provenzi, Francesco Saettini  1 , Valentino Conter, Eugenia Giraldi, Carlo Foglia, Laura Cavalleri, Michele Colledan, Lorenzo D'Antiga, Giorgio Perilongo, Liviana Da Dalt
Affiliations
Review

Is there a role for high dose chemotherapy and blood stem cell rescue in childhood hepatoblastoma presenting with lung metastases? A case report and literature review

Massimo Provenzi et al. Ital J Pediatr. .

Abstract

We report the use of high dose chemotherapy with peripheral blood stem cell rescue as a consolidation treatment for a 3-year-old child affected by metastatic hepatoblastoma, who achieved complete lung response only after conventional treatment. The patient is presently alive 27 months after high dose chemotherapy with blood stem cell rescue with no evidence of disease.The role of high dose chemotherapy with blood stem cell rescue to consolidate the complete clearing of lung disease in metastatic hepatoblastoma remains controversial; the data available in the literature and our experience seems to suggest to keep this treatment option open to further consideration in the clinical setting of high-risk patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard risk hepatoblastoma. N Engl J Med. 2009;39:1662–1670. doi: 10.1056/NEJMoa0810613. - DOI - PubMed
    1. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL 3-HR study. J Clin Oncol. 2010;39:2584–2590. doi: 10.1200/JCO.2009.22.4857. - DOI - PubMed
    1. Trobaugh-Lotrario AD, Katzenstein HM. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies. Pediatr Blood Cancer. 2012;39:809–812. doi: 10.1002/pbc.24219. - DOI - PubMed
    1. Malogolowkin MH, Katzenstein HM, Krailo M, Meyers RL. Treatment of hepatoblastoma: the North American cooperative group experience. Front Biosci. 2012;39:1717–1723. - PubMed
    1. Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall’Igna P, Otte JB, De Camargo B, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P, Perilongo G. et al.Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer. 2012;39:1543–1549. doi: 10.1016/j.ejca.2011.12.011. - DOI - PubMed

MeSH terms